Transgene Biotek Ltd

BSE: 526139

7

total announcements

526139.BO · 15 min delayed

BSECompany Update▼ NegativeResults11 Aug 2026

Transgene Biotek Ltd

Newspaper Publication

Transgene Biotek Ltd published unaudited financial results for the quarter ending June 30, 2026, in newspapers. The results show a net loss of Rs. 38.90 crore, compared to a loss of Rs. 43.37 crore in the same quarter last year. The company's net loss before tax and interest is Rs. 165.29 crore, compared to a loss of Rs. 165.29 crore in the same quarter last year. The company has taken possession of a property bearing No. 468/1, Ward No. 3, D No. 3/85, Ward 3, Eswarreddy Nagar Somulavari Palli Grama Panchayath & Village, Proddatur Mandal, Cuddapah Dist, AP State, measuring 127.77 square yards or 1149.93 SFT, situated at Somulavari Palli Village and Grama Panchayath, Proddatur Caddapah Dist, AP State.

Read more →📎 1 attachment
BSEResultResults7 Aug 2026

Transgene Biotek Ltd

Unaudited Financial Results for the quarter ended 30th June 2026.

Transgene Biotek Ltd has announced its unaudited financial results for the quarter ended 30th June 2026, with a net loss of Rs. 38.90 lakhs. The company's revenue from operations was Rs. 6.00 lakhs, while its expenses were Rs. 44.90 lakhs. The company has also announced the appointment of M/s. Manisha Dubey & Associates as its internal auditors for the financial year 2026-27.

Read more →📎 1 attachment
BSEBoard MeetingResults7 Aug 2026

Transgene Biotek Ltd

Sub: Outcome of the Meeting of the Board of Directors held on August 07, 2026. This has reference to our letter dated 22nd July 2026, Intimating the meeting of the Board of Directors of ....

Transgene Biotek Ltd has announced its unaudited financial results for the quarter ended 30th June 2026, showing a net loss of Rs. 38.90 lakhs. The company has also approved the appointment of M/s. Manisha Dubey & Associates as its internal auditors for the financial year 2026-27.

Read more →📎 1 attachment
BSEOthers22 Jul 2026

Transgene Biotek Ltd

Compliance - 57(4)

Transgene Biotek Ltd has informed that Regulation 57 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is not applicable to the company as there are no non-convertible securities with interest/dividend/principal payable during the quarter ended 30.06.2026.

Read more →📎 1 attachment
BSECompany Update22 Jul 2026

Transgene Biotek Ltd

Statement of Deviation & Variation

Transgene Biotek Ltd has submitted a statement of deviation and variation for the quarter ended June 30, 2026, stating that no public issue, rights issue, or preferential issue occurred during the period, making the submission of the statement not applicable.

Read more →📎 1 attachment
BSEOthers22 Jul 2026

Transgene Biotek Ltd

Compliance -57 (5)

Transgene Biotek Ltd has informed that Regulation 57(5) of SEBI (LODR) Regulations, 2015 is not applicable to the company for the quarter ended June 30, 2026, as no non-convertible securities were issued.

Read more →📎 1 attachment